

# Classification of Distinct Baseline Insulin Infusion Patterns in Children and Adolescents With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Therapy

PAUL-MARTIN HOLTERHUS, MD<sup>1</sup>  
 RAINER ODENDAHL, MD<sup>2</sup>  
 SANDRA OESINGMANN<sup>3</sup>  
 RUDOLF LEPLER, MD<sup>4</sup>  
 VERENA WAGNER, MD<sup>2</sup>

OLAF HIORT, MD<sup>2</sup>  
 REINHARD HOLL, MD<sup>5</sup>  
 THE GERMAN/AUSTRIAN DPV INITIATIVE  
 AND THE GERMAN PEDIATRIC CSII  
 WORKING GROUP

tribution of insulin needs in CSII, which should be kept in mind when considering basal insulin infusion rate strategies in children and adolescents.

*Diabetes Care* 30:568–573, 2007

**OBJECTIVE** — We hypothesized systematic differences in the patterns of programmed basal insulin infusion rates in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion (CSII). We aimed at classification of basal insulin infusion rate regimens and comparing patients' underlying clinical characteristics.

**RESEARCH DESIGN AND METHODS** — The German/Austrian diabetes data acquisition system for prospective surveillance database for quality control and scientific surveys in pediatric diabetology served as the primary data source. Latest (September 2004) basal insulin infusion rates of all 1,248 patients with type 1 diabetes on CSII (0.38–18 years) were analyzed (dataset 1). Basal insulin infusion rates per hour were expressed relative to mean basal insulin infusion rates per 24 h. Unsupervised clustering was used to classify basal insulin infusion rate patterns. Clinical characteristics of patients falling into distinct basal insulin infusion rate clusters were compared by Kruskal-Wallis test. Changes of basal insulin infusion rates in 64 patients were followed from initial settings before CSII to latest programming in an independent dataset 2.

**RESULTS** — Seven different basal insulin infusion rate patterns occurred in dataset 1. A dawn-dusk pattern was used in 708 patients ( $14.9 \pm 2.4$  years) with the peak basal insulin infusion rate at 5 A.M. Additional patterns showed only one basal insulin infusion rate oscillation per 24 h with a backshift of peak basal insulin infusion rates in younger children ( $P < 0.000001$ ) (1 A.M.:  $n = 152$ , 12.4 years and 9 P.M.:  $n = 117$ , 8.9 years). All but two patients in dataset 2 were initially set on dawn-dusk patterns but showed a comparable diversification of basal insulin infusion rates during follow-up with backshift of peak basal insulin infusion rates in younger children ( $P < 0.01$ ).

**CONCLUSIONS** — Pediatric diabetologists shape distinct basal insulin infusion rate profiles during treatment of CSII patients, mainly reflecting differences in age. Our data strongly suggest that age-dependent endocrine changes during childhood (e.g., puberty) affect circadian distri-

Continuous subcutaneous insulin infusion (CSII) therapy has become an increasingly used, effective, safe treatment in children and adolescents with type 1 diabetes (1–5). A growing number of even very young children are treated with CSII (6–8). CSII has been demonstrated to effectively reduce hypoglycemia (3,9–12), while ketoacidotic events are not increased (2,3,6,10). Several studies have demonstrated improvement of metabolic control due to CSII as assessed by A1C (2, 9–13). Compared with multiple daily injections, CSII allows for higher flexibility in timing meals and snacks, which is of particular importance in young children with often unpredictable food intake, enabling intensive treatment with painless insulin delivery.

In addition to the above features and in contrast to multiple daily injection regimens, CSII provides the unique opportunity to program an hourly basal insulin infusion rate, reflecting individual circadian distribution of basal insulin needs. This is of documented (2,10,14) effectiveness in overnight glycemic control in the presence of a “dawn phenomenon” in older children and adults. Children and adolescents undergo dramatic sex-, age-, and puberty-related changes in their endocrine system from birth to adolescence (15,16), involving hormones antagonizing insulin, e.g., IGF-1 (16). Also, sleep patterns and sleep duration change with age during childhood (17,18). Sleep in turn is important for normal growth hormone secretion (19) controlling IGF-1 production. In view of this and of the technical options for basal insulin infusion rate modification in CSII, surprisingly little is known about distinct basal insulin infusion rate patterns in children

From the <sup>1</sup>Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Christian-Albrechts-Universität zu Kiel, Universitätsklinikum Schleswig-Holstein (Campus Kiel), Kiel, Germany; the <sup>2</sup>Department of Pediatrics, Pediatric Endocrinology and Diabetes, Universitätsklinikum Schleswig-Holstein (Campus Lübeck), Lübeck, Germany; the <sup>3</sup>Department of Pediatrics, St. Marien-Hospital, Düren, Germany; the <sup>4</sup>Katholisches Kinderkrankenhaus Wilhelmstift, Hamburg, Germany; and the <sup>5</sup>Department of Epidemiology, University of Ulm, Ulm, Germany.

Address correspondence and reprint requests to Paul-Martin Holterhus, MD, Professor of Pediatrics, Department of Pediatrics, University of Kiel, Schwannenweg 20, 24105 Kiel, Germany. E-mail: holterhus@pediatrics.uni-kiel.de.

Received for publication 11 October 2006 and accepted in revised form 7 November 2006.

**Abbreviations:** CSII, continuous subcutaneous insulin infusion; DCCT, Diabetes Control and Complications Trial; DPV, diabetes data acquisition system for prospective surveillance; SDS, SD score.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

DOI: 10.2337/dc06-2105

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

with type 1 diabetes on CSII. Interestingly, very recently, patient age has been associated with use of different basal insulin infusion rate distributions (4,8). Based on a large, nationwide, German, multicenter cohort of 1,248 pediatric CSII patients, we here present a two-step strategy in which we first identify and characterize existing basal insulin infusion rate patterns (basal insulin infusion rate “phenotypes”) and subsequently analyze the clinical characteristics of the CSII patients falling into these patterns.

## RESEARCH DESIGN AND METHODS

The German/Austrian diabetes data acquisition system for prospective surveillance (DPV) database for quality control and scientific surveys in pediatric diabetology (20,21) served as a primary data source. In all participating centers, data collection was in compliance with the hospital data protection agency. Only anonymized data were transmitted for central analysis. Only the most recent (September 2004) basal insulin infusion rates of all documented 1,248 patients with type 1 diabetes on CSII (0.38–18 years) were considered (dataset 1). Basal insulin infusion rates per hour were expressed relative to mean basal insulin infusion rate per 24 h in percent. We therefore focused on the patterns of basal insulin infusion rate oscillation but not on absolute dosages per hour. To be able to properly compare basal insulin infusion rate values of patients on normal insulin as opposed to fast-acting insulin, analogs were shifted forward by 1 h.

We subsequently performed unsupervised hierarchical average linkage clustering adopted from functional genomics bio-mathematic strategies (22–24) using cluster software (22) to sort the 1,248 individuals according to their basal insulin infusion rate patterns. Results were displayed with TreeView software (22) generating a dendrogram, which reflected the degree of similarity of individuals' basal insulin infusion rates. This in turn makes it possible to distinguish major subgroups of basal insulin infusion rate patterns. Mean  $\pm$  SD for basal insulin infusion rate patterns were calculated for each of the identified basal insulin infusion rate subgroups.

The following clinical characteristics of patients were extracted from the DPV database: age, sex, duration of diabetes, age at manifestation, height SD score (SDS), weight SDS, BMI SDS, total prandial insulin per day, bolus insulin per ki-

logram per day, total basal insulin per day, basal insulin per kilogram per day, total insulin per day, total insulin per kilogram per day, relative fraction of bolus insulin compared with basal insulin, and A1C (Diabetes Control and Complications Trial [DCCT] corrected). Subsequently, we used the Kruskal-Wallis test and Holm correction for multiple testing to assess differences between patient groups.

To test whether basal insulin infusion rate patterns were initially programmed or shaped throughout the course of therapy, data on initial basal insulin infusion rate programming just before the first onset of CSII is needed. As DPV has no systematic information in this respect, we generated a different, independent dataset of 64 patients (dataset 2) in which initial basal insulin infusion rates were retrieved from patients' files. These patients were derived from eight different centers for pediatric diabetology scattered throughout Germany. The initial basal insulin infusion rate and most recent basal insulin infusion rates were considered and clustered as described above for dataset 1.


**RESULTS**— Clustering revealed the existence of seven major basal insulin infusion rate patterns, which we named A through G ( $n = 1,208$ ). The remaining patients did not clearly fall into any of these patterns and were not considered for further evaluation. As pattern E consisted of only 23 of the 1,248 patients, it was also not included in the further discussion. Figure 1 demonstrates cluster analysis, revealing the basal insulin infusion rate patterns. Most patients fell into cluster B ( $n = 708$ , 56.7%), demonstrating a clear dawn-dusk pattern with a higher insulin peak in the early morning than in the late afternoon. Mean age was  $14.9 \pm 2.4$  years, indicating mainly pubertal and postpubertal developmental stages of the patients with this basal insulin infusion rate pattern. A smaller cluster, C ( $n = 83$ , 6.7%), could be distinguished from B, also showing a dawn-dusk pattern but with a less pronounced morning insulin peak. Mean age was slightly younger than in cluster B ( $13.9 \pm 3.9$  years). In addition to these biphasic patterns, four patterns with only one oscillation per 24 h were observed. In pattern D ( $n = 152$ , 12.2%), a broad insulin peak was present with a maximum peak immediately after 12 A.M. (12 A.M.–1 A.M.), while in pattern F ( $n = 117$ , 9.4%), the maxi-

um peak was observed before 12 A.M. (9–10 P.M.). Mean age was  $12.4 \pm 3.6$  years and  $8.9 \pm 4.3$  years (pubertal and prepubertal, respectively). Patterns B, C, D, and F all shared the common feature of relatively low insulin during daytime around 12 A.M. Projecting the curves of patterns B, C, D, and F over each other reveals that decreasing age seems to shift the programmed peak basal rate back in time, leading to a virtual “fusion” of the dawn peak with the dusk peak in the two monophasic patterns D and F (Fig. 2). In contrast, two patterns, A ( $n = 63$ , 5.1%) and G ( $n = 62$ , 5.0%), demonstrated the inverse basal insulin infusion rate distribution with high insulin rates during the daytime but lower insulin during the night (Fig. 1). Mean ages were  $13.9 \pm 4.0$  years and  $11.6 \pm 5.2$  years for patterns A and G, respectively. A and G differed from each other with respect to maximum insulin rates, which occurred during early morning in the older group (A) but in the early evening in the younger group (G).

Kruskal-Wallis with Bonferroni step-down (Holm) correction for multiple testing revealed that patients in the different basal insulin infusion rate groups differed primarily by age ( $P < 0.000001$ ). In addition, duration of diabetes ( $P < 0.000001$ ), age at manifestation ( $P < 0.000001$ ), BMI SDS ( $P < 0.01$ ), total prandial insulin per day ( $P < 0.000001$ ), prandial insulin per kilogram and day ( $P = 0.00005$ ), basal insulin per day ( $P < 0.000001$ ), total insulin per day ( $P < 0.00001$ ), total insulin per kilogram per day ( $P < 0.000001$ ), and A1C (DCCT corrected,  $P = 0.00004$ ) differed significantly between the different cluster groups. In contrast, sex ratio was not significantly associated with specific basal insulin infusion rate patterns.


Patients in cluster B were significantly older than patients in clusters C–F ( $P < 0.0001$  for all comparisons,  $P$  values Bonferroni adjusted). Cluster C patients were younger than B. Cluster D patients were younger than B and older than F. Patients in cluster F were significantly younger than all other groups (all  $P < 0.0001$ , Bonferroni adjusted). Cluster A patients were older than groups F and G.

Multiple logistic regression analysis revealed that age ( $P < 0.0001$ ), standardized BMI ( $P = 0.0002$ ), and bolus insulin requirements ( $P < 0.001$ ) were independent significant predictors of basal insulin infusion rate profiles, while sex, duration of diabetes, and metabolic control did not contribute to this.




**Figure 1**—On the left hand side, the clustering diagram of basal insulin infusion rates of 1,248 different individuals in dataset 1 is displayed (Y-axis). The time course of the basal insulin infusion rates (BRs) is displayed from left to right (X-axis) over four periods of 24 h to show the BR patterns and their rhythms. Increasing red intensity reflects increasing BR while increasing green intensity reflects decreasing BR. Blackish colors reflect BRs near an individual's mean BR. The order of the BRs has been calculated hierarchically by average linkage clustering. The tree in the left margin of the cluster diagram displays the degree of similarity of BR patterns. The most similar BRs cluster right next to each other, thus forming clusters. The pink part of the tree displays an example of a node depicting the dawn-dusk cluster B. The names of the identified BR clusters are displayed in the right margin of the clustering diagram. On the right side of the figure, the mean BRs of all patients in clusters A-G were calculated and are displayed in percent variation from mean BR  $\pm$  SD per cluster.

To achieve more evidence as to whether basal insulin infusion rate patterns were arbitrarily set initially before first treatment and remained unchanged or whether they were successively shaped during treatment and could therefore reflect individual distribution of basal insulin needs, we identified 64 patients (2.4–17.6 years) in eight of the collaborating pediatric diabetes centers in whom the first pump settings had been documented. This is not regularly the case in DPV documentation. Figure 3 demonstrates that most patients were initially set on dawn-dusk basal insulin infusion rates. However, diversification of basal insulin infusion rate patterns evolved during treatment (mean duration  $1.1 \pm 1.2$  years), demonstrating three distinct clusters. We named these clusters  $\alpha$ ,  $\beta$ , and  $\gamma$ . Most of the patients fell into the dawn-dusk group ( $\alpha$ ) ( $n = 28, 43.8\%, 13.3 \pm$



**Figure 2**—The calculated mean basal insulin infusion rates (BRs) from clusters B, C, D, and F were projected over each other. The Y-axis displays the percent deviation of hourly BRs from the mean BR while the X-axis displays a time interval from 5 P.M. to 5 P.M. The right hand side of the figure shows the BR curves. The arrows depict the shift of BR maximum from patterns B/C over D to F back in time with younger age.



**Figure 3**—On the left hand side of the figure, the clustering diagram of initial basal insulin infusion rates (BRs) before first onset of CSII of the 64 patients in dataset 2 is displayed (Y-axis). The color code and description of the tree is the same as in Fig. 1. In the middle part of the figure, only the very last documented BRs were clustered, demonstrating diversification of patterns compared with initial settings. The names of the identified BR clusters are displayed in the right margin of the middle clustering diagram. On the right hand side, the mean BRs of all patients belonging to clusters  $\alpha$ ,  $\beta$  and  $\gamma$  (red, blue, and green, respectively) were calculated and are displayed in percent variation from mean BR  $\pm$  SD per cluster.

4.4 years), supporting our findings in dataset 1. However, a further biphasic dawn-dusk-like cluster ( $\beta$ ) revealed a backshift of the early morning insulin peak to  $\sim$ 3–4 A.M. ( $n = 24$ , 37.5%, age  $12.9 \pm 2.8$  years). A third cluster ( $\gamma$ ) revealed a monophasic basal insulin infusion rate with a broad insulin peak at 9–10 P.M. These children were only  $8.2 \pm 3.7$  years old. While the difference in age between  $\alpha$  and  $\beta$  was not significant,  $t$  tests revealed that differences between  $\beta$  and  $\gamma$  and between  $\alpha$  and  $\gamma$  were highly significant ( $P < 0.001$  and  $P < 0.01$ , respectively). Therefore, basal insulin infusion rate patterns changed during treatment and changes reflected age, supporting analysis in dataset 1.

**CONCLUSIONS**— Using an unsupervised clustering strategy based on a large cohort of pediatric patients with

type 1 diabetes on CSII from Germany and Austria, we demonstrate for the first time the existence of distinct strategies of basal insulin infusion rate distribution over 24 h in the form of defined basal insulin infusion rate clusters. The fact that basal insulin infusion rate regimens change over the course of therapy in our smaller dataset (64 patients) also suggests that basal insulin infusion rate distribution reflects, at least to some extent, individual basal insulin needs. We further show that age is the most important determinant of basal insulin infusion rate clustering. Prandial insulin requirement and age-adjusted BMI are additional, independent, statistically significant contributing factors. In contrast, duration of diabetes or metabolic control achieved (DCCT-adjusted A1C) were not independently related to basal insulin infusion rate clustering, presumably due to their

association with age. Our data are in accordance with two recent studies (4,8) demonstrating age-specific differences in the usage of basal insulin infusion rate patterns in CSII patients.

Children and adolescents undergo comprehensive changes with increasing age from birth to adolescence including circadian rhythms (25), sleep patterns (17,18), growth, and pubertal development sequentially interfering with or altering the endocrine background (15,16,19). These changes are likely to interact in an age-dependent manner with the pattern of insulin sensitivity, thus giving rise to age-dependent differences in the programmed basal insulin infusion rates, as observed in our study. We suggest that pediatric diabetologists should be aware of the existence and shape of these different patterns in order to opti-

mize basal insulin infusion rate regimens in their patients. Prospective studies starting with linear basal rates at initiation of CSII could help to clarify the role of differences in basal insulin infusion rate patterns.

Two patterns (clusters A and G) displayed an unexpected, inverse insulin distribution, with a broad relative insulin peak covering the whole daytime but lower insulin at nighttime. Patients in these clusters were of similar ages to patients in clusters B and D, indicating that factors other than age alone play relevant roles in establishing the particular basal insulin infusion rate patterns in individual patients. We hypothesized that patterns A and G cover the prandial insulin needs in part during the day in addition to the given bolus insulin, thus reflecting individual lifestyle. Unfortunately, it is not possible to retrieve exact underlying information from the anonymized DPV dataset 1 to pin down this phenomenon. In dataset 2, we could not observe this pattern. This is likely due to the small sample size of dataset 2 compared with dataset 1.

**Acknowledgments**—The DPV initiative is supported by the German Ministry of Health, the German Diabetes Association, the German Diabetes Foundation, the Dr. Bürger-Büsing Foundation, the German Medical Association, the National Action Forum against Diabetes Mellitus, and Novo Nordisk Germany.

The Pediatric Pump Working Group is supported by Roche Diagnostics, Germany.

P.-M.H. and R.O. received a research stipend from the Arbeitsgemeinschaft Pädiatrische Diabetologie (AGPD) for this work. Parts of this study were supported by Roche Diagnostics, Germany.

This work is part of the medical thesis of S.O.

We thank M. Petersen and C. Lippelt (Lübeck), B. Heidtmann and G. Discher (Hamburg), H. Olschewski and N. Wagner (Dortmund), E.B. Lang (Coesfeld), U. Schimmel and G. Koch (Hagen), D. Hilgard (Herd-ecke), M. Papsch (Gelsenkirchen), and K.-J. Esser (Düren) for valuable discussions on basal insulin infusion rate management and for support of the project.

The following centers contributed pump data to the study: Aachen, Uni-Kinderklinik RWTH; Aue Helios Kinderklinik; Augsburg Kinderklinik Zentralklinikum; Aurich Kinderklinik; Bad Aibling Internist; Praxis; Bad Hersfeld Kinderklinik; Bad Oeynhausen Diabetesfachklinik; Berlin Kinderklinik Lindenhof; Berlin Virchow-Kinderklinik; Bielefeld Kinderklinik Gilead; Bonn Uni-Kinderklinik; Bremen-Kinderklinik Nord;

Bremen Kinderklinik St. Jürgenstrasse; Bremerhaven Kinderklinik; Celle Kinderklinik; Chemnitz Kinderklinik; Coesfeld Kinderklinik; Delmenhorst Kinderklinik; Detmold Kinderklinik; Dornbirn Kinderklinik; Dortmund Kinderklinik; Dresden Uni-Kinderklinik; Düren-Birkedorf Kinderklinik; Düsseldorf Uni-Kinderklinik; Erfurt Kinderklinik; Erlangen Uni-Kinderklinik; Essen Elisabeth Kinderklinik; Essen Uni-Kinderklinik; Esslingen Städtische Kinderklinik; Eutin Kinderklinik; Freiburg Uni-Kinderklinik; Friedrichshafen Kinderklinik; Fulda Kinderklinik; Fürth Kinderklinik; Garmisch-Partenkirchen Kinderklinik; Gelsenkirchen Kinderklinik Marienhospital; Gießen Uni-Kinderklinik; Graz Universitäts-Kinderklinik; Göppingen Kinderklinik am Eichert; Göttingen Uni-Kinderklinik; Hagen Kinderklinik; Halle Uni-Kinderklinik; Hamburg Altonaer Kinderklinik; Hamburg Kinderklinik Wilhelmstift; Hamburg-Nord Kinderklinik Heidberg; Hamm Kinderklinik; Hanau Kinderklinik; Hannover Kinderklinik MHH; Hannover Kinderklinik auf der Bult; Heidelberg Uni-Kinderklinik; Heidenheim Kinderklinik; Heilbronn Kinderklinik; Herford Kinderarztpraxis; Herford Kinderklinik; Heringsdorf Inselklinik; Hermeskeil Kinderpraxis; Hildesheim Innere; Hildesheim Kinderarztpraxis; Hildesheim Kinderklinik; Hinrichsegen-Bruckmühl Diabetikerjugendhaus; Homburg Uni-Kinderklinik Saarland; Innsbruck Universitätskinderklinik; Itzehoe Kinderklinik; Jena Uni-Kinderklinik; Kaiserslautern-Westpfalz-Klinikum Kinderklinik; Karlsburg Diabetesfachklinik; Karlsruhe Städtische Kinderklinik; Kassel Kinderklinik Park Schönfeld; Kaufbeuren Innere Medizin; Kiel Städtische Kinderklinik; Kiel Universitäts-Kinderklinik; Koblenz Kinderklinik Kemperhof; Köln Kinderklinik Amsterdamerstrasse; Köln Uni-Kinderklinik; Leipzig Uni-Kinderklinik; Leverkusen Kinderklinik; Lingen Kinderklinik St. Bonifatius; Ludwigsburg Kinderklinik; Ludwigshafen Kinderklinik St. Anna-Stift; Lübeck Uni-Kinderklinik; Lüdenscheid Kinderklinik; Magdeburg Uni-Kinderklinik; Mainz Uni-Kinderklinik; Mannheim Uni-Kinderklinik; Mechernich Kinderklinik; Memmingen Kinderklinik; Merzig Kinderklinik; Moers Kinderklinik; Mutterstadt Kinderarztpraxis; Mönchengladbach Kinderklinik; Rheydt Elisabethkrankenhaus; München von Haunersche Kinderklinik; München-Harlaching Kinderklinik; Münster St. Franziskus Kinderklinik; Münster Uni-Kinderklinik; Münster pädiat Schwerpunktpraxis; Neuburg Kinderklinik; Neunkirchen Kinderklinik Kohlhof; Neuss Lukaskrankenhaus Kinderklinik; Neuwied Kinderklinik Elisabeth; Nürnberg Cnopfsche Kinderklinik; Oberhausen Kinderklinik; Offenbach/Main Kinderklinik; Oldenburg Kinderklinik; Osnabrück Kinderklinik; Paderborn St. Vincenz Kinderklinik; Passau Kinderarztpraxis Handwerker; Passau Kinderklinik; Pforzheim Kinderklinik; Rastatt Ge-

meinschaftspraxis; Ravensburg Kinderklinik St. Nikolaus; Regensburg Kinderklinik St. Hedwig; Remscheid Kinderklinik; Rendsburg Kinderklinik; Rheine Mathiaspital Kinderklinik; Rosenheim Kinderklinik; Rotenburg/Wümme Kinderklinik; Saalfeld Thüringenklinik Kinderklinik; Saarlouis Kinderklinik; Schweinfurt Kinderklinik; Schwerin Kinderklinik; Siegen Kinderklinik; Singen-Hegauklinik Kinderklinik; Stade Kinderklinik; Stuttgart Olgahospital Kinderklinik; Suhl Kinderklinik; Sylt Rehaklinik; Traunstein Praxis Dr. Voll; Trier Kinderklinik der Borromäerinnen; Ulm Uni-Kinderklinik, Vechta Kinderklinik; Waiblingen Kinderklinik; Waldshut Kinderpraxis Biberbau; Weingarten Kinderarztpraxis; Wien Uni-Kinderklinik; Wiesbaden Horst-Schmidt-Kinderklinik; Wiesbaden Kinderklinik DKD; Worms Kinderklinik; Wuppertal Kinderklinik.

## References

1. Pickup J, Keen H: Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. *Diabetes Care* 25:593–598, 2002
2. Tamborlane WV, Fredrickson LP, Ahern JH: Insulin pump therapy in childhood diabetes mellitus: guidelines for use. *Treat Endocrinol* 2:11–21, 2003
3. Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV: Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. *Pediatrics* 114:1601–1605, 2004
4. Danne T, von Schutz W, Lange K, Nestoris C, Datz N, Kordonouri O: Current practice of insulin pump therapy in children and adolescents: the Hannover recipe. *Pediatr Diabetes* 7:25–31, 2006
5. Heidtmann B, Lepler R, Klinkert C, Deiss D, Grabert M, Holl RW für die AG Insulinpumpentherapie im Kindes- und Jugendalter und die DPV-Wiss-Initiative Insulinpumpentherapie bei Kindern und Jugendlichen mit diabetes mellitus Type 1 in Deutschland: Insulin pump therapy in children and adolescents in Germany. *Monatsschr Kinderheilkd* 153:947–953, 2005
6. Fox LA, Buckloh LM, Smith SD, Wysocki T, Maura N: A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. *Diabetes Care* 28:1277–1281, 2005
7. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE: A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. *Diabetes Care* 28:15–19, 2005
8. Danne T, Battelino T, Kordonouri O, Hannas R, Klinkert C, Ludvigsson J, Barrio R,

- Aebi C, Gschwend S, Mullis PE, Schumacher U, Zumsteg U, Morandi A, Rabbone I, Cherubini V, Toni S, de Beaufort C, Hindmarsh P, Sumner A, van Waarde WM, van den Berg N, Phillip M: A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. *Pediatr Diabetes* 6:193–198, 2005
9. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV: Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. *Diabetes Care* 22:1779–1784, 1999
  10. Kaufman FR, Halvorson M, Miller D, Mackenzie M, Fisher LK, Pitukcheewanont P: Insulin pump therapy in type 1 pediatric patients: now and into the year 2000. *Diabetes Metab Res Rev* 15:338–352, 1999
  11. Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, Tamborlane WV: Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. *Pediatr Diabetes* 3:10–15, 2002
  12. Sulli N, Shashaj B: Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. *J Pediatr Endocrinol Metab* 16:393–399, 2003
  13. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. *Diabetes Care* 27:1554–1558, 2004
  14. Geffner ME, Frank HJ, Kaplan SA, Lippe BM, Levin SR: Early-morning hyperglycemia in diabetic individuals treated with continuous subcutaneous insulin infusion. *Diabetes Care* 6:135–139, 1983
  15. Dunger DB, Matthews DR, Edge JA, Jones J, Preece MA: Evidence for temporal coupling of growth hormone, prolactin, LH and FSH pulsatility overnight during normal puberty. *J Endocrinol* 130:141–149, 1991
  16. Lofqvist C, Andersson E, Gelerander L, Rosberg S, Blum WF, Albertsson Wikland K: Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. *J Clin Endocrinol Metab* 86:5870–5876, 2001
  17. Roffwarg HP, Muzio JN, Dement WC: Ontogenetic development of the human sleep-dream cycle. *Science* 152:604–619, 1966
  18. Howard BJ, Wong J: Sleep disorders. *Pediatr Rev* 22:327–342, 2001
  19. Redwine L, Hauger RL, Gillin JC, Irwin M: Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. *J Clin Endocrinol Metab* 85:3597–3603, 2000
  20. Wagner VM, Grabert M, Holl RW, the German Initiative on Quality Control in Pediatric Diabetology: Severe hypoglycemia, metabolic control and diabetes management in children with type 1 diabetes in the decade after the Diabetes Control and Complications Trial: a large scale multicenter study. *Eur J Pediatr* 164:73–79, 2005
  21. Grabert M, Schweiggert F, Holl RW: A framework for diabetes documentation and quality management in Germany: 10 years of experience with DPV computer methods and programs. *Biomedicine* 69:115–121, 2002
  22. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 95:14863–14868, 1998
  23. Holterhus PM, Hiort O, Demeter J, Brown PO, Brooks JD: Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor. *Genome Biol* 4:R37, 2003
  24. Bebermeier JH, Brooks JD, Deprimo SE, Werner R, Deppe U, Demeter J, Hiort O, Holterhus PM: Cell-line and tissue-specific signatures of androgen receptor-coreceptor transcription. *J Mol Med* 84:919–931, 2006
  25. Löhr B, Siegmund R: Ultradian and circadian rhythms of sleep-wake and food-intake behavior during early infancy. *Chronobiol Int* 16:129–148, 1999